Cancer Tissue Diagnostics Market Latest Concepts, Overview Outlook by 2027 with Prominent Key Players Abbott, Enzo Life Sciences, Agilent Technologies, Cancer Genetics

Cancer is among the leading cause of deaths across the globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer.

Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.
Additionally, cancer is found to be commonly prevalent in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in the UK were due to cancer.

Get Sample Copy of the Report at – http://tiny.cc/sf0s9y

Prominent Key Players Operating in this Study Include:

- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Abcam plc.

The global cancer tissue diagnostics market is US$ 2,025.41 Mn in 2018 and is predicted to grow at a CAGR of 6.2% during the forecast period 2019 – 2027, to reach US$ 3,419.61 Mn by 2027.

What the report features:-

- Global analysis of Cancer Tissue Diagnostics market from 2017 – 2027 illustrating the progression of the market.

- Forecast and analysis of Cancer Tissue Diagnostics market by Dosage, Route of Administration and Application from 2017 – 2027

- Forecast and analysis of Cancer Tissue Diagnostics market in five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America

Europe is the second largest geographic market and is expected to be the second most significant revenue contributor in forecast period. The region has witnessed several technological advancements in the field of healthcare by the incorporation of advanced cancer tissue diagnostics in order to increase the efficiency of treatments in the region. The growth is driven by factors such as prevalence of cancer in the countries, increased mortality rates as well as growth strategies adopted by the market players in the European countries.

Asia Pacific region is also facing the problem of the growing prevalence of cancer. The top 15 countries with Cancer prevalence are Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India, total deaths due to cancer were 784,821. These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Hence, driving the growth of the cancer tissue diagnostics market during the forecast period.
Growing Investments for Tissue Diagnostics

Tissue diagnostics is very crucial in cancer treatment. Cancer tissue diagnostics play a significant role in determining the treatment pace and procedure. Early detection can help in reducing the mortality rates of cancer; hence, medical professionals, market players as well as government authorities implementing new diagnostics and treatment facilities. Thus the rise in investments and better reimbursement policies favor the growth of the cancer tissue diagnostics market.

For instance, in September 2017, OncoStem Diagnostics, invested USD 6 million towards research and development to develop useful tests for brain, colon and oral cancer, and also to automate these tests. Furthermore, Fimmic, which is now, Aiforia Technologies Oy in 2017 invested €5 million to develop, WebMicroscope AI Cloud for tissue diagnostics. Fimmic’s WebMicroscope launched in early 2017, is a tissue diagnostic commercial platform that enables image analysis through deep learning artificial intelligence (AI). In 2019, the company launched AIforia cloud platform, which accelerates image processing and provides automated pathology image analysis. Thus the growing investments for cancer tissue diagnostics have led to the advent of breakthrough techniques, expecting to fuel the growth of the market.

Get Discount on this Report at – http://tiny.cc/5g0s9y

Test Type Insights

The global cancer tissue diagnostics market by test type was led by immunohistochemical tests segment. In 2018, the immunohistochemical tests segment held a largest market share of the cancer tissue diagnostics market, by test type. In addition, the immunohistochemical tests segment is also expected to grow at the fastest rate during the coming years owing to cost effectiveness of the technique. Moreover, the technique is easily accessible, and growth in number of products based on technology. Additionally, the rising prevalence of cancer is a major factor for the growth of the diagnostic tests. The segment is also anticipated to witness growth at a significant rate during the forecast period, 2019 to 2027.

Strategic Insights

There have been limited developments made in the cancer tissue diagnostics market during recent years. However, growth strategies such as approvals, collaborations, and partnerships have been witnessed in the market of cancer tissue diagnostics. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Also, during November 2018, Leica Biosystems, launched the latest PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform.

CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

• Immunohistochemical Tests
o Breast Cancer
o Colorectal Cancer
o Prostate Cancer
o Stomach Cancer
o Others

• In Situ Hybridization Tests

o Breast Cancer
o Lung Cancer
o Bladder Cancer
o Others

Purchase this Report at – http://tiny.cc/8i0s9y

Reasons to Buying this Qualitative Report –

- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Global Cancer Tissue Diagnostics Market.

- Highlights key business priorities in order to assist companies to realign their business strategies.

- The key findings and recommendations highlight crucial progressive industry trends in the Cancer Tissue Diagnostics, thereby allowing players to develop effective long term strategies.

- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com/

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

This release was published on openPR.